Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | CASR | P41180 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905689 | 0.83 | KMT2A (0.53) | KMT2ACASRKCNH2RORCTSHR | |
| SCHEMBL4909063 | 0.81 | KMT2A (0.54) | KMT2AKCNH2RORCMEN1CYP19A1 | |
| SCHEMBL4907872 | 0.78 | KMT2A (0.41) | KMT2AMCL1KCNH2RORCMEN1 | |
| SCHEMBL4911111 | 0.77 | KMT2A (0.51) | KMT2AMCL1RORCTSHRMEN1 | |
| SCHEMBL4908613 | 0.77 | KMT2A (0.51) | KMT2ARORCTSHRMEN1CYP19A1 | |
| SCHEMBL8415398 | 0.77 | KMT2A (0.56) | KMT2ARORCTSHRMEN1HTT | |
| SCHEMBL4910736 | 0.77 | KMT2A (0.40) | KMT2AMCL1KCNH2RORCTSHR | |
| SCHEMBL5705666 | 0.75 | KMT2A (0.43) | KMT2ACASRTSHRCYP19A1PKM | |
| SCHEMBL29605983 | 0.75 | KMT2A (0.54) | KMT2ARORCTSHRMEN1PKM | |
| SCHEMBL4906648 | 0.75 | KMT2A (0.54) | KMT2AMCL1TSHRMEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-08-21 | — | — | US | claimed |
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-04-19 | — | — | US | claimed |
| US-20070082893-A1 | Active substance combination | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-04-12 | — | — | US | claimed |
| EP-1755678-A2 | ACTIVE SUBSTANCE COMBINATION OF A CARBINOL COMPOUND AND AN OPIOID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-28 | — | — | EP | claimed |
| EP-1746986-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A CARBINOL COMBINED TO AT LEAST AN NSAID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-31 | — | — | EP | claimed |
| WO-2005097192-A9 | ACTIVE SUBSTANCE COMBINATION OF A CARBINOL COMPOUND AND AN OPIOID | ESTEVE LABOR DR (ES) | 2007-01-18 | — | — | WO | claimed |
| EP-1695704-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-30 | — | — | EP | claimed |
| WO-2006087147-A2 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS FOR THE TREATMENT OF FIBROMYALGIA | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-24 | — | — | WO | claimed |
| EP-1690537-A1 | Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-16 | — | — | EP | claimed |
| EP-1642577-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of central neuropathic pain | Laboratorios del Dr. Esteve S.A. (ES) | 2006-04-05 | — | — | EP | claimed |
| EP-1632227-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols (in particular cizolirtin citrate) for the treatment of opioid addiction | Laboratorios del Dr. Esteve S.A. (ES) | 2006-03-08 | — | — | EP | claimed |
| US-20060040924-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of renal colic | LABORATORIOS DR. ESTEVE S.A. (ES) | 2006-02-23 | — | — | US | claimed |
| WO-2005097192-A2 | ACTIVE SUBSTANCE COMBINATION OF A CARBINOL COMPOUND AND AN OPIOID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-20 | — | — | WO | claimed |
| WO-2005097099-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A CARBINOL COMBINED TO AT LEAST AN NSAID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-20 | — | — | WO | claimed |
| EP-1584335-A2 | Active substance combination comprising a carbinol composition and an opioid | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-12 | — | — | EP | claimed |
| US-20050222136-A1 | Active substance combination | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-10-06 | — | — | US | claimed |
| US-20050222135-A1 | Active substance combination | LABORATIONS DEL DR. ESTEVE S.A. (ES) | 2005-10-06 | — | — | US | claimed |
| EP-1103243-B1 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES FOR THE TREATMENT OF TROUBLES MEDIATED BY AN EXCESS OF SUBSTANCE P | ESTEVE LABOR DR (ES) | 2004-01-07 | — | — | EP | claimed |
| EP-1103243-A2 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF TROUBLES MEDIATED BY AN EXCESS OF SUBSTANCE P | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-05-30 | — | — | EP | claimed |
| EP-0289380-B1 | Aryl-heteroaryl-carbinol derivatives having an analgesic activity | ESTEVE LABOR DR (ES) | 1994-12-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222135-A1 | Active substance combination | OPRM1, OPRK1, OPRL1 | KMT2A 1439/4885CASR 3822/4885MCL1 3820/4885 |
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | PTGS1, PTGS2, PTGES2 | KMT2A 3087/4885CASR 3757/4885MCL1 2734/4885 |
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | CNR2, CNR1, HCRTR2 | KMT2A 1689/4885CASR 1765/4885MCL1 4171/4885 |
| US-20050222136-A1 | Active substance combination | PTGS1, MMP8, TACR1 | KMT2A 2783/4885CASR 3146/4885MCL1 4138/4885 |
| US-20060040924-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of renal colic | SLC10A2, FABP2, FANCI | KMT2A 2641/4885CASR 2276/4885MCL1 2262/4885 |
| US-20070082893-A1 | Active substance combination | OPRM1, OPRK1, OPRL1 | KMT2A 1439/4885CASR 3822/4885MCL1 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.